Lerer Kenneth B's Form 4 filing
Strata Critical Medical, Inc. (SRTA) · filed Aug 17, 2022
- Accession no.
- 0001779128-22-000089
- Filed
- Aug 17, 2022
- Trade date
- Aug 15-16, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $403.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lerer Kenneth BCIK 0001120789 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −25,943 | $6.34F1 | −$164,478.62 | 73,386 | Indirect | |
| Aug 15, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −13,883 | $6.34F1 | −$88,018.22 | 39,271 | Indirect | |
| Aug 16, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −15,654 | $6.27F5 | −$98,150.58 | 57,732 | Indirect | |
| Aug 16, 2022 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −8,376 | $6.27F5 | −$52,517.52 | 30,895 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These transactions were executed in multiple trades at prices ranging from $6.25 to $6.64, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 2 transactions in Table I.
- F5
These transactions were executed in multiple trades at prices ranging from $6.25 to $6.305, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 2 transactions in Table I.